Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inoclim is a nutritional and botanical supplement developed by Laboratoire Innotech International for the management of menopausal symptoms, particularly vasomotor symptoms such as hot flashes and night sweats. The product is formulated as an oral capsule containing 40 mg of a standardized soy extract rich in the isoflavones daidzin and genistin. These phytoestrogens are non-steroidal compounds that possess a structural similarity to 17β-estradiol, allowing them to bind to estrogen receptors and exert weak estrogenic effects. This activity helps to mitigate the physiological impacts of declining endogenous estrogen levels during menopause. Inoclim is marketed as a pharmaceutical-grade supplement and has demonstrated efficacy and safety in clinical evaluations involving menopausal populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Inoclim.